{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:05Z","timestamp":1790983145559,"version":"4.1.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus, eczematous lesions, and significant impairment of quality of life. In severe or chronic cases, AD can present with diverse atypical phenotypes, among which prurigo nodularis (PN)-like lesions are clinically challenging due to their recalcitrance to conventional therapies. Patients with severe AD are also at an increased risk of comorbid immune-mediated diseases, such as alopecia areata (AA), a non-scarring hair loss disorder driven by aberrant immune responses. Ivarmacitinib, a highly selective oral Janus kinase 1 (JAK1) inhibitor, has been approved by the National Medical Products Administration (NMPA) of China for moderate-to-severe atopic dermatitis (April 2025) and alopecia areata (June 2025). Herein, we report a case of a 28-year-old male patient with a long-standing history of AD who developed generalized PN-like lesions and concurrent AA (with a 2-year disease duration) and androgenetic alopecia (AGA). Conventional therapies including topical corticosteroids and antihistamines failed to yield satisfactory outcomes. Following treatment with ivarmacitinib (8 mg once daily), the patient showed rapid improvements in skin lesions, pruritus, and hair regrowth. This case suggests that ivarmacitinib may be beneficial for complex AD phenotypes with comorbid immune-mediated hair loss.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1836241","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:37:26Z","timestamp":1785476246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaofan","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]},{"name":"Medical School, Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]},{"name":"Medical School, Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02202-z","article-title":"Ivarmacitinib sulfate: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.044","article-title":"Ivarmacitinib for the treatment of adults with severe alopecia areata: results from a phase 3 trial","volume":"94","author":"Zhou","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Dermatovenerol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.07.010","article-title":"The role of Janus kinase signaling in the pathology of atopic dermatitis","volume":"152","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1961352","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1836241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:05:44Z","timestamp":1787058344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1836241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1836241"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1836241","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1836241"}}